1. Dopamine induces apoptosis in APPswe-expressing Neuro2A cells following Pepstatin-sensitive proteolysis of APP in acid compartments.
- Author
-
Cagnin M, Ozzano M, Bellio N, Fiorentino I, Follo C, and Isidoro C
- Subjects
- Amyloid Precursor Protein Secretases metabolism, Amyloid beta-Peptides metabolism, Amyloid beta-Protein Precursor genetics, Animals, Apoptosis genetics, Carbamates pharmacology, Cathepsin D metabolism, Cell Line, Tumor, Chloroquine pharmacology, Dipeptides pharmacology, Dose-Response Relationship, Drug, Endocytosis drug effects, Gene Expression Regulation, Neoplastic drug effects, Green Fluorescent Proteins genetics, Humans, In Situ Nick-End Labeling, Lysosomes drug effects, Mice, Mitochondrial Membranes drug effects, Neuroblastoma pathology, Neuroblastoma ultrastructure, Phorbol Esters pharmacology, Protein Biosynthesis drug effects, Proteolysis drug effects, RNA, Small Interfering pharmacology, Transfection methods, bcl-2-Associated X Protein metabolism, Amyloid beta-Protein Precursor metabolism, Apoptosis drug effects, Dopamine pharmacology, Pepstatins pharmacology, Protease Inhibitors pharmacology
- Abstract
A pathological hallmark of Alzheimer's disease (AD) is the presence within neurons and the interneuronal space of aggregates of β-amyloid (Aβ) peptides that originate from an abnormal proteolytic processing of the amyloid precursor protein (APP). The aspartyl proteases that initiate this processing act in the Golgi and endosomal compartments. Here, we show that the neurotransmitter dopamine stimulates the rapid endocytosis and processing of APP and induces apoptosis in neuroblastoma Neuro2A cells over-expressing transgenic human APP (Swedish mutant). Apoptosis could be prevented by impairing Pepstatin-sensitive and acid-dependent proteolysis of APP within endosomal-lysosomal compartments. The γ-secretase inhibitor L685,458 and the α-secretase stimulator phorbol ester elicited protection from dopamine-induced proteolysis of APP and cell toxicity. Our data shed lights on the mechanistic link between dopamine excitotoxicity, processing of APP and neuronal cell death. Since AD often associates with parkinsonian symptoms, which is suggestive of dopaminergic neurodegeneration, the present data provide the rationale for the therapeutic use of lysosomal activity inhibitors such as chloroquine or Pepstatin A to alleviate the progression of AD leading to onset of parkinsonism., (Copyright © 2012 Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF